Gyre Therapeutics (GYRE) EPS (Weighted Average and Diluted) (2010 - 2026)
Gyre Therapeutics (GYRE) reported EPS (Weighted Average and Diluted) of -$0.1 for Q1 2026, down 400.0% quarter-over-quarter from -$0.02 in Q4 2025.
Gyre Therapeutics (GYRE) EPS (Weighted Average and Diluted) (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.1 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.1, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.09 (down 550.0% YoY), and the FY2025 annual result was $0.02, down 60.0% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$0.1 in Q1 2026 per GYRE's latest filing, from -$0.02 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $1.64 in Q2 2022 and troughed at -$1.51 in Q4 2023.
- A 5-year average of -$0.12 and a median of $0.01 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 356.25% in 2022 and fell as far as 100.0% in 2022.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.28 in 2022, then slipped by 17.97% to -$1.51 in 2023, then soared by 100.66% to $0.01 in 2024, then sank by 300.0% to -$0.02 in 2025, then tumbled by 400.0% to -$0.1 in 2026.
- Business Quant data shows GYRE's EPS (Weighted Average and Diluted) at -$0.1 in Q1 2026, -$0.02 in Q4 2025, and $0.03 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | -0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.10 |
| Dec 31, 2025 | -0.02 |
| Sep 30, 2025 | 0.03 |
| Sep 30, 2024 | 0.01 |
| Jun 30, 2024 | 0.01 |
| Mar 31, 2024 | 0.03 |
| Dec 31, 2023 | -1.51 |
| Sep 30, 2023 | 0.05 |
| Jun 30, 2023 | 0.02 |
| Mar 31, 2023 | 0.03 |
| Dec 31, 2022 | -1.28 |
| Sep 30, 2022 | -0.16 |
| Jun 30, 2022 | 1.64 |
| Mar 31, 2022 | -0.46 |
| Dec 31, 2021 | -0.64 |
| Sep 30, 2021 | -0.80 |
| Jun 30, 2021 | -0.64 |
| Sep 30, 2013 | -0.38 |
| Jun 30, 2013 | -0.37 |
| Mar 31, 2013 | -0.24 |